NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

Phase 1

Completed

Conditions: Dengue Virus

Interventions: Other: Placebo
Biological: Investigational Vaccine for Dengue Virus Subtype 2

First Posted Date: 2010-02-23

Last Posted Date: 2013-01-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 18

Registration Number: NCT01073306

Locations: 🇺🇸
Johns Hopkins Project SAVE, Center for Immunization Research, Washington, District of Columbia, United States

Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine

Phase 1

Completed

Conditions: Dengue

Interventions: Biological: TetraVax-DV Vaccine-Admixture 1
Biological: TetraVax-DV Vaccine-Admixture 2
Biological: TetraVax-DV Vaccine-Admixture 3
Biological: TetraVax-DV Vaccine-Admixture 4
Biological: Placebo
Biological: TetraVax-DV Vaccine-Admixture 5

First Posted Date: 2010-02-22

Last Posted Date: 2013-01-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 141

Registration Number: NCT01072786

Locations: 🇺🇸
Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
🇺🇸
Fletcher Allen Health Care (FAHC), General Clinical Research Center (GCRC), Burlington, Vermont, United States
🇺🇸
University of Vermont Vaccine Testing Center, Burlington, Vermont, United States

Tuberculosis in China

Completed

Conditions: Tuberculosis
Tuberculosis, Multidrug-Resistant
Extensively Drug Resistant Tuberculosis

First Posted Date: 2010-02-19

Last Posted Date: 2018-04-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 199

Registration Number: NCT01071603

Locations: 🇨🇳
Henan Provincial Chest Hospital, Zhengzhou, China

Empiric Therapy of Mucopurulent Cervicitis (MPC)

Phase 3

Terminated

Conditions: Cervicitis
Vaginitis Bacterial

Interventions: Other: Placebo
Drug: Azithromycin
Drug: Cefixime

First Posted Date: 2010-02-19

Last Posted Date: 2014-12-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 87

Registration Number: NCT01072136

Locations: 🇺🇸
University of Mississippi - Infectious Diseases, Jackson, Mississippi, United States
🇺🇸
Harbor UCLA Medical Center - OBGYN - General Gynecology and Women's Health, Torrance, California, United States
🇺🇸
Louisiana Stte University - Health Sciences Center - Medicine, New Orleans, Louisiana, United States

and more 1 locations

Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding

Completed

Conditions: HIV Infections

Interventions: Drug: Tenofovir disoproxil fumarate (TDF)

First Posted Date: 2010-02-10

Last Posted Date: 2022-09-23

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1765

Registration Number: NCT01066858

Locations: 🇺🇬
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Mpigi, Uganda
🇿🇦
Umlazi CRS, Durban, KwaZulu-Natal, South Africa
🇿🇦
Durban Paediatric HIV CRS, Durban, KwaZulu-Natal, South Africa

and more 8 locations

Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System

Completed

Conditions: Chronic Granulomatous Disease (CGD)
Atherosclerosis

First Posted Date: 2010-02-05

Last Posted Date: 2021-07-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 156

Registration Number: NCT01063309

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

Phase 1

Withdrawn

Conditions: Influenza

Interventions: Drug: Peramivir

First Posted Date: 2010-02-05

Last Posted Date: 2011-11-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT01063933

Locations: 🇺🇸
University of Massachusetts, Worcester, Massachusetts, United States
🇺🇸
North Shore-Long Island Jewish Health System, Manhasset, New York, United States
🇺🇸
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States

and more 26 locations

Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Zidovudine (ZDV)
Other: Discontinue triple ARVs
Drug: Lamivudine-Zidovudine (3TC-ZDV)
Other: Continue triple ARVs
Other: No Intervention
Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail
Drug: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])
Drug: Lopinavir-ritonavir (LPV-RTV)

First Posted Date: 2010-02-02

Last Posted Date: 2022-02-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 3747

Registration Number: NCT01061151

Locations: 🇹🇿
Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania
🇿🇦
Shandukani Research CRS, Johannesburg, Gauteng, South Africa
🇲🇼
Malawi CRS, Lilongwe, Malawi

and more 11 locations

Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: HIV-1 DNA plasmid vaccine
Biological: HIV-1 recombinant Ad5 vaccine

First Posted Date: 2010-01-22

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8

Registration Number: NCT01054872

Locations: 🇺🇸
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States
🇺🇸
Seattle Vaccine and Prevention CRS, Seattle, Washington, United States

Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

Phase 2

Completed

Conditions: Influenza A
Influenza B

Interventions: Biological: Anti-Influenza Immune Plasma
Drug: Standard Care

First Posted Date: 2010-01-20

Last Posted Date: 2017-09-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 98

Registration Number: NCT01052480

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Los Angeles Biomedical Research Institute, CA, Torrance, California, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

and more 32 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy